Skip to content

Cardinal Health

US · CAH #429 by market cap Listed 1970
272.81 +0.47 +0.17%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Official SEC filings

Source: SEC EDGAR. Latest available cached filings; filing date is not the financial period end. Index checked: 2026-11-22 02:43 UTC.

FormFiledOriginal document
8-K2026-11-16Read on SEC.gov
10-Q2026-11-05Read on SEC.gov
8-K2026-11-05Read on SEC.gov
8-K2026-10-01Read on SEC.gov
10-K2026-08-11Read on SEC.gov
8-K2026-08-11Read on SEC.gov
8-K2026-08-11Read on SEC.gov
8-K2026-08-05Read on SEC.gov

SEC annual financial snapshot

Standard US-GAAP facts in 10-K filings, USD. Income and cash flow cover the annual period; balance-sheet amounts are as of period end. These are not quarterly or TTM figures. Latest available filed values may include restatements; reporting periods can differ from other providers. Checked: 2026-11-21 17:51 UTC.

MetricUSDBasisPeriod endFiledSource
Revenue$254.25BAnnual2026-06-302026-08-1110-K
Net income$1.71BAnnual2026-06-302026-08-1110-K
Operating cash flow$5.17BAnnual2026-06-302026-08-1110-K
Total assets$57.30BAs of2026-06-302026-08-1110-K
Stockholders’ equity$-2.88BAs of2026-06-302026-08-1110-K
Cash and cash equivalents$4.86BAs of2026-06-302026-08-1110-K

✦ Quant Financial Health how this is computed

Good
  • Altman Z-Score is 5.19, above the 3.0 "safe zone" threshold.
  • Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

✦ Quant Revenue Concentration how this is computed

Single-engine
  • Pharmaceutical and Specialty Solutions is the largest reported line at 92.70% of revenue, across 4 reported segments.
  • The next-largest line, Global Medical Products and Distribution (GMPD), is a distant second at 4.73% - a sharp slowdown here would have little to offset it.

Revenue annual, last 8 years

Latest year +14.23% YoY

Margins

Gross margin
3.84%
Operating margin
1.25%
Net margin
0.67%

Key ratios & quality

PEG uses trailing P/E against the 3-year net income growth rate (73.18%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Revenue 145.53B152.92B162.47B181.33B204.98B226.83B222.58B254.25B
Gross profit 6.83B6.87B6.78B6.48B6.87B7.41B8.17B9.77B
Selling & admin expenses 4.48B4.57B4.53B4.51B4.80B5.00B5.38B6.13B
Research & development ----------------
Operating profit 1.73B1.77B1.79B1.65B1.79B2.13B2.32B3.17B
Pretax profit 1.75B-3.77B323.00M-784.00M663.00M1.20B2.10B2.17B
Tax 386.00M-79.00M-289.00M153.00M332.00M348.00M532.00M469.00M
Net profit 1.37B-3.69B612.00M-937.00M331.00M853.00M1.57B1.71B
Basic EPS 5-132-31367
Diluted EPS 4.53-12.612.08-3.371.263.456.457.23

Balance sheet

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Total current assets 25.75B25.94B31.05B32.94B33.74B34.88B36.37B38.75B
Cash & ST investments 2.53B2.77B3.41B4.72B4.08B5.13B3.87B4.86B
Inventory 12.82B13.20B14.59B15.64B16.12B14.96B16.83B17.30B
Total assets 40.96B40.77B44.45B43.88B43.35B45.12B53.12B57.30B
Total current liabilities 24.11B23.62B27.62B30.55B33.74B35.64B38.90B43.90B
Short-term debt 452.00M10.00M871.00M580.00M792.00M434.00M550.00M1.88B
Long-term debt 7.58B6.77B5.37B4.74B3.91B4.66B7.98B7.00B
Total liabilities 34,633,000,000.0038,974,000,000.0042,659,000,000.0044,584,000,000.0046,306,000,000.0048,333,000,000.0055,756,000,000.0060,023,000,000.00
Total equity 6.33B1.79B1.79B-706.00M-2.96B-3.21B-2.63B-2.72B
Retained earnings 5.43B1.17B1.21B-280.00M-642.00M-286.00M783.00M2.01B

Cash flow

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Operating cash flow 2.72B1.96B2.43B3.18B2.84B3.76B2.40B5.17B
Depreciation & amortization 1.00B913.00M783.00M692.00M692.00M710.00M790.00M956.00M
Free cash flow 2.39B1.59B2.03B2.79B2.36B3.25B1.85B4.53B
Dividends paid -577.00M-569.00M-573.00M-559.00M-525.00M-499.00M-494.00M-491.00M
Stock buybacks / issuance -600.00M-350.00M-200.00M-1.00B-2.00B-750.00M-765.00M-1.36B
Ending cash balance 2.53B2.77B3.41B4.75B4.08B5.13B3.87B4.86B

Returns & efficiency

Line item 2019 2020 2021 2022 2023 2024 2025 2026
ROE % 22.01-91.0734.13-172.46--------
ROA % 3.37-9.041.43-2.110.601.923.183.10
ROIC % 10.82-30.218.95-13.02--------
5-year avg ROE % 17.35-4.70-2.33-40.87--------
EBIT margin % 1.41-2.310.31-0.340.360.551.040.99
FCF / sales % 1.651.041.251.511.151.430.831.78
Current ratio 1.071.101.121.081.000.980.940.88
Quick ratio 0.460.470.450.500.450.480.440.43
Debt / assets 19.6116.6214.0312.1110.8411.2916.0515.51
LT debt / equity 119.77378.14299.55----------
Interest coverage 6.96-14.852.79-4.167.8624.5510.777.25
Revenue CAGR (3Y) % 6.195.575.907.6010.2611.777.077.44
Net income CAGR (3Y) % -1.52--33.64----11.72--73.18
FCF CAGR (3Y) % -1.5125.75-5.235.2114.2417.02-12.7824.18

Revenue breakdown most recent period

Business

Pharmaceutical and Specialty Solutions92.70%
Global Medical Products and Distribution (GMPD)4.73%
Other2.61%

Quote time 2026-11-20 20:02:34 · For reference only, not investment advice and not tailored to your situation.

Cardinal Health discussion 0 comments

Add a comment